CDX
SU-DHL-8
Tumor indication
Lymphoma
Tumor subtype
DLBCL (GCB)
Description
SU-DHL-8 (Lymphoma CDX Model)
The SU-DHL-8 cell line was derived from diffuse large B-cell lymphoma (DLBCL). It provides a reproducible system for hematology drug discovery. SU-DHL-8 reflects aggressive B-cell malignancy biology. Its consistent growth supports translational lymphoma pipelines.
Key Features:
- Derived from diffuse large B-cell lymphoma.
- Represents aggressive B-cell disease.
- Suspension culture phenotype.
- Tumorigenic in xenografts.
Applications:
SU-DHL-8 is used in preclinical testing of novel lymphoma therapies. It supports biomarker validation and drug resistance research. Researchers apply it to study B-cell signaling pathways. Its reproducibility ensures value for translational hematology research.
Details
- Tumor indication
- Lymphoma
- Tumor subtype
- DLBCL (GCB)
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.